GLP1R and chronic kidney disease: However, when selecting an agent, one should bear in mind that, although GLP1-RA have been considered effective in the reduction of atherosclerotic events, including myocardial infarction and stroke, whereas SGLT-2i in the reduction of incident HF [106,107,108], the latter may be superior than the former in DM patients: 1) with more than three cardiovascular risk factors without established CV disease or CKD, 2) with established CV disease and CKD, 3) committed to further reducing their risk for CVD and CKD outcomes [109].